Trametinib is a reversible, highly selective, allosteric inhibitor of MEK1 and MEK2, which is FDA approved for melanoma, lung cancer, and anaplastic thyroid cancers with BRAF mutations. This evidence concerns the gene MAP2K1 and thyroid gland undifferentiated (anaplastic) carcinoma.